# Harmony Biosciences Shares Fall 7% as Wakix Patent Arguments Unfold

By Enna Lee

Canonical URL: https://www.tokenpost.com/news/investing/39008
Published: 2026-10-23T13:35:36.000Z
Updated: 2026-10-23T13:35:36.000Z
Section: Investing

> Arguments were underway Thursday in Wilmington, Delaware, in an ANDA patent case involving AET Pharma.

Harmony Biosciences Holdings, Inc. (HRMY) shares fell 7% on Oct. 22 as closing arguments were underway in a patent dispute over Wakix, the company’s drug.

The arguments were taking place Thursday in Wilmington, Delaware, in ANDA patent litigation between Harmony and AET Pharma.